Can PACE provide access to any other wider enabling capabilities?

As part of PACE support, we are tackling barriers to AMR therapeutic and diagnostic development by connecting global innovators with UK national capabilities to help shape and drive projects forward. One such cross-cutting collaboration established is with the UK Health Security Agency (UKHSA) to enable early evaluation of in vitro antimicrobial activity across the PACE therapeutic portfolio. We are continually assessing the AMR ecosystem to identify additional capabilities that can strengthen delivery of our portfolio of projects and address common gaps within data packages. To find out more about enabling technologies and capabilities, please visit the Partnerships page.